Induced pluripotent stem cells
It was one of the top science stories of 2007: number 2 on Science's list – reprogramming ordinary adult body cells (of mice and humans) to act like embryonic stem cells. (See here for summary.) As Science put it,
The story really began in October 2006, when a team at Kyoto University in Japan, led by Shinya Yamanaka, announced that they had reprogrammed mouse skin cells into cells that closely resembled embryonic stem cells, based on certain characteristic genes that were expressed. The reprogramming was done by introducing genes for four important stem cell transcription factors (Oct4 (or sometimes the similar Oct3), Sox2, c-Myc, and Klf4) into the skin cells with the help of a genetically engineered retrovirus. (See here for more about Oct4.)
But the team could not at that time demonstrate that these reprogrammed cells would differentiate into a variety of adult cells after having been introduced into a mouse embryo which then developed into an adult mouse. Being able to do this would verify the pluripotency of the reprogrammed cells. (Pluripotency is the ability of a cell to develop into any type of fetal or adult cell. It is characteristic of embryonic stem cells.) The reprogrammed cells are called induced pluripotent stem (iPS) cells.
However, in June 2007 Yamanaka's team, along with two others, reported that they had been able to provide the missing demonstration of pluripotency. The second team that joined in reporting this accomplishment was led by Rudolf Jaenisch at MIT's Whitehead Institute for Biomedical Research. The third team was led jointly by Konrad Hochedlinger of the Harvard Stem Cell Institute and Kathrin Plath of the UCLA Institute for Stem Cell Biology and Medicine. (References: here, here, here, here, here, here, here, here, here.)
The crucial step, of course, was being able to reprogram adult human cells in the same way. For all anyone knew, this might be quite difficult. However, just five months later, in November 2007, Yamanaka's team, together with another led by James Thomson of the University of Wisconsin, announced that this objective had been accomplished. (References: here, here, here, here, here, here, here, here, here, here.)
Yamanaka's team used the same four transcription factors for the human cells as they used for the mouse cells. The cells they reprogrammed were adult human fibroblasts. Thomson's team also used Sox2 and Oct3/4, but instead of c-Myc and Klf4 they used other transcription factors: Nanog and Lin28. The cells they reprogrammed were fetal or newborn fibroblasts.
Very soon thereafter, the Japanese team announced that they could also dispense with c-Myc. That was good, because c-Myc is linked with cancer, as we discussed here. But the downside was that the process was much slower and less efficient. (References: here, here.)
In early December the Jaenisch tean from the Whitehead Institute collaborated with a team led by Tim Townes of the University of Alabama to show that their mouse iPS cells could treat a mouse model of sickle cell anemia. Specifically, they started with skin cells from sickle cell mice and made iPS cells. They also added a corrected hemoglobin gene, and then let the cells differentiate into blood-producing stem cells. When these cells were placed in mice whose defective blood stem cells had been killed, healthy red blood cells were eventually produced, alleviating the symptoms of sickle cell disease. (References: here, here, here, here, here, here, here.)
Of course, it's far too early to attempt such an experiment with humans. All concerns about the possiblity of cancer developing from the iPS cells would need to be cleared away. Then the procedure would need to be tested carefully using a lengthy series of clinical trials.
In late December, a team led by George Daley from Harvard Medical School and Children's Hospital in Boston announced thay they had also been able to convert ordinary human skin cells into embryonic-like stem cells. (See here.) The team had also programmed iPS cells from mesenchymal stem cells (adult stem cells found in bone marrow that can differentiate into fat, bone and cartilage).
Recently (mid-February), Kathrin Plath's team at UCLA has also announced success in reprogramming human skin cells, using the same techniques as previously reported. They have also verified that the induced pluripotent cells are very similar to embryonic stem cells:
Human Skin Cells Reprogrammed Into Embryonic Stem Cells (2/11/08)
As we've noted, there have been some potential problems with the work already mentioned. First, any process that activates c-Myc (directly or indirectly) runs risks of promoting cancerous tumors. Second, the processes have used retroviruses to introduce the necessary genetic material into cells to be reprogrammed. This also runs the risk of inducing cancer.
So Konrad Hochedlinger's team has come along with work in mice to reduce or remove these cancer-causing risks:
Discovery Could Help Reprogram Adult Cells To Embryonic Stem Cell-like State (2/15/08)
And hard on their heels, other teams are announcing similar findings:
Stem cell breakthrough may reduce cancer risk (2/27/08)
More: here.
Additional reading:
Tags: stem cells, induced pluripotent stem cells
The riddle of Dolly the Sheep has puzzled biologists for more than a decade: What is it about the oocyte that rejuvenates the nucleus of a differentiated cell, prompting the genome to return to the embryonic state and form a new individual? This year, scientists came closer to solving that riddle. In a series of papers, researchers showed that by adding just a handful of genes to skin cells, they could reprogram those cells to look and act like embryonic stem (ES) cells.
The story really began in October 2006, when a team at Kyoto University in Japan, led by Shinya Yamanaka, announced that they had reprogrammed mouse skin cells into cells that closely resembled embryonic stem cells, based on certain characteristic genes that were expressed. The reprogramming was done by introducing genes for four important stem cell transcription factors (Oct4 (or sometimes the similar Oct3), Sox2, c-Myc, and Klf4) into the skin cells with the help of a genetically engineered retrovirus. (See here for more about Oct4.)
But the team could not at that time demonstrate that these reprogrammed cells would differentiate into a variety of adult cells after having been introduced into a mouse embryo which then developed into an adult mouse. Being able to do this would verify the pluripotency of the reprogrammed cells. (Pluripotency is the ability of a cell to develop into any type of fetal or adult cell. It is characteristic of embryonic stem cells.) The reprogrammed cells are called induced pluripotent stem (iPS) cells.
However, in June 2007 Yamanaka's team, along with two others, reported that they had been able to provide the missing demonstration of pluripotency. The second team that joined in reporting this accomplishment was led by Rudolf Jaenisch at MIT's Whitehead Institute for Biomedical Research. The third team was led jointly by Konrad Hochedlinger of the Harvard Stem Cell Institute and Kathrin Plath of the UCLA Institute for Stem Cell Biology and Medicine. (References: here, here, here, here, here, here, here, here, here.)
The crucial step, of course, was being able to reprogram adult human cells in the same way. For all anyone knew, this might be quite difficult. However, just five months later, in November 2007, Yamanaka's team, together with another led by James Thomson of the University of Wisconsin, announced that this objective had been accomplished. (References: here, here, here, here, here, here, here, here, here, here.)
Yamanaka's team used the same four transcription factors for the human cells as they used for the mouse cells. The cells they reprogrammed were adult human fibroblasts. Thomson's team also used Sox2 and Oct3/4, but instead of c-Myc and Klf4 they used other transcription factors: Nanog and Lin28. The cells they reprogrammed were fetal or newborn fibroblasts.
Very soon thereafter, the Japanese team announced that they could also dispense with c-Myc. That was good, because c-Myc is linked with cancer, as we discussed here. But the downside was that the process was much slower and less efficient. (References: here, here.)
In early December the Jaenisch tean from the Whitehead Institute collaborated with a team led by Tim Townes of the University of Alabama to show that their mouse iPS cells could treat a mouse model of sickle cell anemia. Specifically, they started with skin cells from sickle cell mice and made iPS cells. They also added a corrected hemoglobin gene, and then let the cells differentiate into blood-producing stem cells. When these cells were placed in mice whose defective blood stem cells had been killed, healthy red blood cells were eventually produced, alleviating the symptoms of sickle cell disease. (References: here, here, here, here, here, here, here.)
Of course, it's far too early to attempt such an experiment with humans. All concerns about the possiblity of cancer developing from the iPS cells would need to be cleared away. Then the procedure would need to be tested carefully using a lengthy series of clinical trials.
In late December, a team led by George Daley from Harvard Medical School and Children's Hospital in Boston announced thay they had also been able to convert ordinary human skin cells into embryonic-like stem cells. (See here.) The team had also programmed iPS cells from mesenchymal stem cells (adult stem cells found in bone marrow that can differentiate into fat, bone and cartilage).
Recently (mid-February), Kathrin Plath's team at UCLA has also announced success in reprogramming human skin cells, using the same techniques as previously reported. They have also verified that the induced pluripotent cells are very similar to embryonic stem cells:
Human Skin Cells Reprogrammed Into Embryonic Stem Cells (2/11/08)
The reprogrammed cells were not just functionally identical to embryonic stem cells. They also had identical biological structure, expressed the same genes and could be coaxed into giving rise to the same cell types as human embryonic stem cells.
As we've noted, there have been some potential problems with the work already mentioned. First, any process that activates c-Myc (directly or indirectly) runs risks of promoting cancerous tumors. Second, the processes have used retroviruses to introduce the necessary genetic material into cells to be reprogrammed. This also runs the risk of inducing cancer.
So Konrad Hochedlinger's team has come along with work in mice to reduce or remove these cancer-causing risks:
Discovery Could Help Reprogram Adult Cells To Embryonic Stem Cell-like State (2/15/08)
Harvard Stem Cell Institute (HSCI) and Massachusetts General Hospital (MGH) researchers have taken a major step toward eventually being able to reprogram adult cells to an embryonic stem cell-like state without the use of viruses or cancer-causing genes.
In a paper released online today by the journal Cell Stem Cell, Konrad Hochedlinger and colleagues report that they have discovered how long adult cells need to be exposed to reprogramming factors before they convert to an embryonic-like state, and have “defined the sequence of events that occur during reprogramming.”
This work on adult mouse skin cells should help researchers narrow the field of candidate chemicals and proteins that might be used to safely turn these processes on and off. This is particularly important because at this stage in the study of these induced pluripotent (iPS) cells, researchers are using cancer-causing genes to initiate the process, and are using retroviruses, which can activate cancer genes, to insert the genes into the target cells. As long as the work involves the use of either oncogenes or retroviruses, it would not be possible to use these converted cells in patients.
And hard on their heels, other teams are announcing similar findings:
Stem cell breakthrough may reduce cancer risk (2/27/08)
The main obstacle to using "reprogrammed" human stem cells – the danger that they might turn cancerous – has been solved, claims a US company.
PrimeGen, based in Irvine, California, says that its scientists have converted specialised adult human cells back to a seemingly embryonic state – using methods that are much less likely to trigger cancer than those deployed previously.
The company also claims to be able to produce reprogrammed cells faster and much more efficiently than other scientists.
More: here.
Additional reading:
- Redefining What is Embryonic Stem Cell: Nuclear Reprogramming and Epigenetic Remodeling of Fibroblasts – announcement of a talk on March 3, 2008 by Kathrin Plath, describing her reprogramming work.
- Reprogramming Battle: Egg Vs. Virus – an editorial with review of technical information, published online in Stem Cells, November 29, 2007
- Field Leaps Forward With New Stem Cell Advances – November 23, 2007 news article in Science about the first reported successes of reprogramming human skin cells into cells that act like embryonic stem cells
- Induced Pluripotent Stem Cell Lines Derived from Human Somatic Cells – research article in Science that is described in the preceding news article
- Teams Reprogram Differentiated Cells--Without Eggs – June 8, 2007 news article in Science about the reprogramming of mouse cells
- Reprogramming, Take Two – June 8, 2007 news article in Science about research on another approach to reprogramming, which achieved reprogramming of mouse somatic cells using zygotes whose nuclear DNA has been removed
Tags: stem cells, induced pluripotent stem cells
Labels: Myc, pluripotency, stem cells
Subscribe to posts
0 Comments:
Post a Comment
<< Home